Shimadzu's new LC-30A Nexera is unsurpassed in high-speed and high-resolution analysis and productivity. It meets the needs of the most demanding markets such as pharmaceutical and the food industry.
UHPLC systems represent the latest development in liquid chromatography instrumentation. Beside enhancements necessary to operate with sub 2 µm particle columns, they differ from each other through their versatility in handling various applications on the same instrument without any changes.
Shimadzu’s new LC-30A Nexera is unsurpassed in high-speed and high-resolution analysis and productivity. It meets the needs of the most demanding markets such as pharmaceutical and the food industry.
Nexera pumps offer a flow range from 0.0001 ml/min up to 3ml/min with 130 MPa pressure and from 3.0001 up to 5 ml/min with 80 MPa pressure. This allows the use of longer columns for covering fast LC with high flow rates and short columns as well as highest resolution using long columns.
The new developed micro-reactor based mixer supports a small system volume and very short gradient delays. The Nexera autosampler provides reduced carryover compared to the previous instruments by keeping the direct injection with isolated metering system principle using 3 rinse solvents, various rinsing modes and design changes at needle and needle seal. To increase the throughput overlapping pre-treatment can be used. The pre-treatment capabilities expand the application range of this instrument.
The control unit contains a modified software in order to control the new modules and functionalities, e.g. the autosampler.
In addition to UV and PDA detectors, the brand-new and worldwide most sensitive and fastest RF-20A/20AXS fluorescence detectors can be applied with Nexera.
LC-30A Nexera can be used for semi-micro, conventional and UHPLC methods without changes on the flowline. It fulfils the demands of an all-round LC system with high reliability and robustness.
For further details please visit www.shimadzu.eu/nexera
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.